326 related articles for article (PubMed ID: 19189305)
1. Low stroma androgen receptor level in normal and tumor prostate tissue is related to poor outcome in prostate cancer patients.
Wikström P; Marusic J; Stattin P; Bergh A
Prostate; 2009 Jun; 69(8):799-809. PubMed ID: 19189305
[TBL] [Abstract][Full Text] [Related]
2. Altered expression of androgen receptor in the malignant epithelium and adjacent stroma is associated with early relapse in prostate cancer.
Henshall SM; Quinn DI; Lee CS; Head DR; Golovsky D; Brenner PC; Delprado W; Stricker PD; Grygiel JJ; Sutherland RL
Cancer Res; 2001 Jan; 61(2):423-7. PubMed ID: 11212224
[TBL] [Abstract][Full Text] [Related]
3. A stroma targeted therapy enhances castration effects in a transplantable rat prostate cancer model.
Johansson A; Jones J; Pietras K; Kilter S; Skytt A; Rudolfsson SH; Bergh A
Prostate; 2007 Nov; 67(15):1664-76. PubMed ID: 17854058
[TBL] [Abstract][Full Text] [Related]
4. Nuclear androgen receptors recur in the epithelial and stromal compartments of malignant and non-malignant human prostate tissue several months after castration therapy.
Wikström P; Ohlson N; Stattin P; Bergh A
Prostate; 2007 Sep; 67(12):1277-84. PubMed ID: 17597113
[TBL] [Abstract][Full Text] [Related]
5. Androgen and prostatic stroma.
Niu YJ; Ma TX; Zhang J; Xu Y; Han RF; Sun G
Asian J Androl; 2003 Mar; 5(1):19-26. PubMed ID: 12646998
[TBL] [Abstract][Full Text] [Related]
6. Androgen receptor levels in prostate cancer epithelial and peritumoral stromal cells identify non-organ confined disease.
Ricciardelli C; Choong CS; Buchanan G; Vivekanandan S; Neufing P; Stahl J; Marshall VR; Horsfall DJ; Tilley WD
Prostate; 2005 Apr; 63(1):19-28. PubMed ID: 15378523
[TBL] [Abstract][Full Text] [Related]
7. Castration-induced epithelial cell death in human prostate tissue is related to locally reduced IGF-1 levels.
Ohlson N; Bergh A; Stattin P; Wikström P
Prostate; 2007 Jan; 67(1):32-40. PubMed ID: 16998819
[TBL] [Abstract][Full Text] [Related]
8. Expression of AR associated protein 55 (ARA55) and androgen receptor in prostate cancer.
Miyoshi Y; Ishiguro H; Uemura H; Fujinami K; Miyamoto H; Miyoshi Y; Kitamura H; Kubota Y
Prostate; 2003 Sep; 56(4):280-6. PubMed ID: 12858356
[TBL] [Abstract][Full Text] [Related]
9. Expression of insulin-like growth factor-1 receptor in local and metastatic prostate cancer.
Ryan CJ; Haqq CM; Simko J; Nonaka DF; Chan JM; Weinberg V; Small EJ; Goldfine ID
Urol Oncol; 2007; 25(2):134-40. PubMed ID: 17349528
[TBL] [Abstract][Full Text] [Related]
10. Androgen receptor expression in clinically localized prostate cancer: immunohistochemistry study and literature review.
Qiu YQ; Leuschner I; Braun PM
Asian J Androl; 2008 Nov; 10(6):855-63. PubMed ID: 18958349
[TBL] [Abstract][Full Text] [Related]
11. Differently regulated androgen receptor transcriptional complex in prostate cancer compared with normal prostate.
Kinoshita M; Nakagawa T; Shimizu A; Katsuoka Y
Int J Urol; 2005 Apr; 12(4):390-7. PubMed ID: 15948728
[TBL] [Abstract][Full Text] [Related]
12. Co-assessment of cytoplasmic and nuclear androgen receptor location in prostate specimens: potential implications for prostate cancer development and prognosis.
Diallo JS; Aldejmah A; Mouhim AF; Fahmy MA; Koumakpayi IH; Sircar K; Bégin LR; Mes-Masson AM; Saad F
BJU Int; 2008 May; 101(10):1302-9. PubMed ID: 18294307
[TBL] [Abstract][Full Text] [Related]
13. Reactive stroma as a predictor of biochemical-free recurrence in prostate cancer.
Ayala G; Tuxhorn JA; Wheeler TM; Frolov A; Scardino PT; Ohori M; Wheeler M; Spitler J; Rowley DR
Clin Cancer Res; 2003 Oct; 9(13):4792-801. PubMed ID: 14581350
[TBL] [Abstract][Full Text] [Related]
14. Insulin-like growth factor (IGF)-I, IGF-II and IGF type I receptor (IGFR-I) expression in prostatic cancer.
Cardillo MR; Monti S; Di Silverio F; Gentile V; Sciarra F; Toscano V
Anticancer Res; 2003; 23(5A):3825-35. PubMed ID: 14666684
[TBL] [Abstract][Full Text] [Related]
15. Higher tumor to benign ratio of the androgen receptor mRNA expression associates with prostate cancer progression after radical prostatectomy.
Rosner IL; Ravindranath L; Furusato B; Chen Y; Gao C; Cullen J; Sesterhenn IA; McLeod DG; Srivastava S; Petrovics G
Urology; 2007 Dec; 70(6):1225-9. PubMed ID: 18158066
[TBL] [Abstract][Full Text] [Related]
16. Androgen receptor versus erbB-1 and erbB-2 expression in human prostate neoplasms.
Brys M; Stawinska M; Foksinski M; Barecki A; Zydek C; Miekos E; Krajewska WM
Oncol Rep; 2004 Jan; 11(1):219-24. PubMed ID: 14654929
[TBL] [Abstract][Full Text] [Related]
17. Heterogeneity of androgen receptor content in advanced prostate cancer.
Magi-Galluzzi C; Xu X; Hlatky L; Hahnfeldt P; Kaplan I; Hsiao P; Chang C; Loda M
Mod Pathol; 1997 Aug; 10(8):839-45. PubMed ID: 9267828
[TBL] [Abstract][Full Text] [Related]
18. Androgen receptor gene amplification and protein expression in recurrent prostate cancer.
Ford OH; Gregory CW; Kim D; Smitherman AB; Mohler JL
J Urol; 2003 Nov; 170(5):1817-21. PubMed ID: 14532783
[TBL] [Abstract][Full Text] [Related]
19. Nuclear androgen receptor staining in bone metastases is related to a poor outcome in prostate cancer patients.
Crnalic S; Hörnberg E; Wikström P; Lerner UH; Tieva A; Svensson O; Widmark A; Bergh A
Endocr Relat Cancer; 2010 Dec; 17(4):885-95. PubMed ID: 20688881
[TBL] [Abstract][Full Text] [Related]
20. Prognostic value of the androgen receptor and its coactivators in patients with D1 prostate cancer.
Mori R; Wang Q; Quek ML; Tarabolous C; Cheung E; Ye W; Groshen S; Hawes D; Togo S; Shimada H; Danenberg KD; Danenberg PV; Pinski JK
Anticancer Res; 2008; 28(1B):425-30. PubMed ID: 18383880
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]